Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 7Uveal Melanoma 2Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Gastrointestinal Stromal Tumors 2Colorectal Neoplasms 2Solid Tumors Harboring a BRAF V600 Mutation 1Solid Tumor 1Soft Tissue Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1Biliary Tract Neoplasms 1Advanced BRAF Mutant Cancers 1

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × binimetinib × Clear all
NCT02285439 2025-10-07

Study of MEK162 for Children With Low-Grade Gliomas

Children's Hospital Los Angeles

Phase 1/2 Completed
105 enrolled 17 charts
CNS

Brain Neoplasms, Soft Tissue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡